Comment: Phase III assessment of topotecan, cyclophosphamide and high-dose ifosfamide for refractory Ewing sarcoma patients

Share :
Published: 5 Jun 2022
Views: 37
Dr Julie Gralow- Chief Medical Officer, ASCO

Dr Julie Gralow comments on a study on chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES). rEECur is the first randomised controlled trial in this setting.

The primary outcome was event-free survival (EFS) for the phase III comparison. Secondary outcomes included overall survival (OS), toxicity, and quality of life (QoL).

Dr Gralow concludes the by discussing the significance of the study findings.

Watch Dr McCabe's press conference on the study here

Watch Dr McCabe's interview on the study here

Read the news story here